These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 1320362

  • 41. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
    Rotstein C, Amsterdam D, Beam TR, Mandell LA, Gorzynski EA.
    Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
    [Abstract] [Full Text] [Related]

  • 42. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R, Andrews JM, Brenwald N.
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [Abstract] [Full Text] [Related]

  • 43. In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
    Rolston KV, Nguyen H, Messer M, LeBlanc B, Ho DH, Bodey GP.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2263-6. PubMed ID: 2127348
    [Abstract] [Full Text] [Related]

  • 44. Comparative in vitro activity of a new quinolone, AM-1091.
    Neu HC, Novelli A, Chin NX.
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1036-41. PubMed ID: 2675753
    [Abstract] [Full Text] [Related]

  • 45. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.
    Mandell W, Neu HC.
    Antimicrob Agents Chemother; 1986 May; 29(5):852-7. PubMed ID: 3729343
    [Abstract] [Full Text] [Related]

  • 46. Antimicrobial activity of CS-940, a new trifluorinated quinolone.
    Biedenbach DJ, Sutton LD, Jones RN.
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2325-30. PubMed ID: 8619590
    [Abstract] [Full Text] [Related]

  • 47. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative.
    Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H.
    Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909
    [Abstract] [Full Text] [Related]

  • 48. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
    Gargallo-Viola D, Esteve M, Llovera S, Roca X, Guinea J.
    Antimicrob Agents Chemother; 1991 Mar; 35(3):442-7. PubMed ID: 2039195
    [Abstract] [Full Text] [Related]

  • 49. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R, Brenwald NP, Andrews JM, Boswell F.
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [Abstract] [Full Text] [Related]

  • 50. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [Abstract] [Full Text] [Related]

  • 51. Comparative in vitro activity of sparfloxacin (AT 4140, RP 64206--SPFX) against 275 multiresistant clinical isolates.
    Giamarellou H, Voutsinas D, Xirouchaki E.
    J Chemother; 1992 Feb; 4(1):12-5. PubMed ID: 1328554
    [Abstract] [Full Text] [Related]

  • 52. In vitro activity of OPC-17116.
    Neu HC, Fang W, Gu JW, Chin NX.
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [Abstract] [Full Text] [Related]

  • 53. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.
    Waites KB, Duffy LB, Schmid T, Crabb D, Pate MS, Cassell GH.
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1181-5. PubMed ID: 1929260
    [Abstract] [Full Text] [Related]

  • 54. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [Abstract] [Full Text] [Related]

  • 55. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC, Chin NX.
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [Abstract] [Full Text] [Related]

  • 56. In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative.
    Asahara M, Tsuji A, Goto S, Masuda K, Kiuchi A.
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1144-52. PubMed ID: 2679369
    [Abstract] [Full Text] [Related]

  • 57. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.
    Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T.
    Antimicrob Agents Chemother; 1996 May; 40(5):1201-7. PubMed ID: 8723467
    [Abstract] [Full Text] [Related]

  • 58. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [Abstract] [Full Text] [Related]

  • 59. Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent.
    Gargallo-Viola D, Esteve M, Moros M, Coll R, Xicota MA, de Andres C, Roser R, Guinea J.
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2318-26. PubMed ID: 2088187
    [Abstract] [Full Text] [Related]

  • 60. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
    Visalli MA, Jacobs MR, Appelbaum PC.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.